Advertisement

International Journal of Hematology

, Volume 85, Issue 2, pp 173–174 | Cite as

Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy

  • Seiichi Okabe
  • Tetsuzo Tauchi
  • Yuko Ishii
  • Daigo Akahane
  • Kousuke Nunoda
  • Seiko Honda
  • Tomoiku Takaku
  • Kazuma Ohyashiki
Article

Keywords

Imatinib Imatinib Mesylate Chronic Myeloid Leukemia Patient Imatinib Therapy Imatinib Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome- positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873–2878.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994–1004.PubMedCrossRefGoogle Scholar
  3. 3.
    Sumi M, Tauchi T, Sashida G, et al. Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients. Clin Lab Haematol. 2005;27:416–417.PubMedCrossRefGoogle Scholar
  4. 4.
    Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol. 2004;76:275–278.PubMedCrossRefGoogle Scholar
  5. 5.
    Cortes J, O’Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004; 104:2204–2205.PubMedCrossRefGoogle Scholar
  6. 6.
    Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28(suppl 1):S71-S73.PubMedCrossRefGoogle Scholar
  7. 7.
    Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979–981.PubMedGoogle Scholar
  8. 8.
    Ghanima W, Kahrs J, Dahl TG 3rd,Tjonnfjord GE. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol. 2004;72:441–443.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Seiichi Okabe
    • 1
  • Tetsuzo Tauchi
    • 1
  • Yuko Ishii
    • 1
  • Daigo Akahane
    • 1
  • Kousuke Nunoda
    • 1
  • Seiko Honda
    • 1
  • Tomoiku Takaku
    • 1
  • Kazuma Ohyashiki
    • 1
  1. 1.First Department of Internal MedicineTokyo Medical UniversityTokyoJapan

Personalised recommendations